Our Board
Independent Non-Executive Chairman
Mr Greg Hutchinson
Greg has held leadership roles in rapidly scaling clinical services delivery for over 30 years, spending the last 13 as the CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services, subsidiaries of Sonic Healthcare Limited (ASX: SHL) an S&P/ASX 100 company. Having graduated with First Class Honours in Physiotherapy (Bachelor of Applied Science) in 1989, Greg went on to establish a successful chain of private physiotherapy clinics throughout Australia. In the process, he completed Post Graduate studies in Sports Physiotherapy and enjoyed professional appointments with a variety of professional sporting clubs, events and teams.
Non-Executive Director
Professor Sir John Tooke
Sir John has 30 years’ experience as a consultant physician. He is Chair of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI) UCL and chaired oversight on the Academy of Medical Sciences project ‘How we best use scientific evidence to judge the benefits and harms of medicines’. Sir John is a Non-Executive Director of BUPA Chile and chairs the Medical Advisory Council.
Non-Executive Director
Dr Karen Smith
Dr Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor in the US, Europe, Canada and Asia. Her breadth of experience covers over 100 clinical trials and 20+ major regulatory approvals in multiple jurisdictions, including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan); leading to product launches across diverse therapeutic areas including areas in oncology, rare disease, cardiology, dermatology, neuroscience, and anti-infectives. In addition to R&D and pipeline development, Dr Smith’s successful record of business development includes acquisitions, divestitures, and partnership deals.
Non-Executive Director
Dr Mohit Kaushal
Dr. Mohit Kaushal is a healthcare tech entrepreneur and investor, serving as an advisor at General Atlantic LLC and on the board of five other companies. With a focus on mental health, he has held notable positions at Humedica, Rxante, and Change Healthcare, as well as having been involved in healthcare initiatives during the Obama administration and collaborating with the FDA at the Federal Communications Commission.
CEO & Managing Director
Dr Michael Winlo
Michael has extensive experience in leading high-growth teams. Prior to Emyria, he served as CEO of Linear Clinical Research and, before that, lived in Silicon Valley where he worked for Palantir, helping major healthcare institutions in the US and UK solve complex data integration and analysis challenges. Michael is a medical doctor with an MBA from Stanford.
Management Team
Head of Preclinical Drug Development
Tatjana Heinrich
Tatjana Heinrich is a highly experienced Group Lead in Preclinical Drug Development with a strong background in Biotechnology. Her expertise lies in Drug Discovery, Project Management, Molecular Biology, Peptide Chemistry, Protein Expression, and Bioinformatics. She holds a PhD in Biochemistry and Molecular Biology from Freie Universität Berlin, showcasing her dedication to advancing this field. Tatjana’s leadership skills and vast experience in this critical domain drive Emyria’s innovative research and development to improve patient outcomes.
Project Manager
Adrienne Smith
Adrienne has over a decade of experience coordinating complex projects and tenders across a range of industries and helping individuals and organisations visualise – and improve – their processes. Prior to joining Emyria, she worked in various process improvement roles at Linear Clinical Research, and before that, she worked as a bid manager, travelling around the country to help the likes of PwC, Spotless, and G4S win new business.
Chemistry, Manufacturing & Controls Lead
Claudia Sullivan
Claudia is a Chemistry, Manufacturing, and Controls Lead who has dedicated her extensive career to the pharmaceutical industry. With close to a decade of experience in Pharmaceutical Manufacturing and in a Phase One clinical trials unit, Claudia has honed her expertise in clinical research and pharmaceutical product manufacturing. She excels in managing Quality Control, Quality Assurance, Quality Systems, Regulatory and Compliance, all while maintaining stringent Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards.
Clinical Advisory Board
Dr Jennifer Morgan
Dr Morgan is an anaesthetist and pain specialist. She established the first private pain services at St John of God Hospital and Hollywood Hospital in Western Australia. Her interests include the prevention of acute pain developing into chronic pain and chronic pain conditions, such as neuropathic pain.
Dr Jon Laugharne
Consultant psychiatrist and specialist in treatment of psychological trauma. Trained psychedelic therapist and MDMA-assisted therapy researcher.
Claire Kullack
Trauma-informed mental health nurse, psychotherapist and nationally recognised EMDR trainer. Trained in psychedelic-assisted therapy and MDMA researcher.
Prof. Matt Piggot
Professor and specialist in amphetamine chemistry and novel drug design.
Dr Jeremy Tannenbaum
Dual specialist in Pain Medicine and Psychiatry. Researched psychedelics at Imperial College, London.
